# BSP-12-CADONILIMAB

## Executive Summary

| Property | Value |
|----------|-------|
| **Drug** | Cadonilimab |
| **Targets** | PD-1 Ã— CTLA-4 |
| **Indication** | Cervical/Gastric Cancer |
| **Innovation** | Optimized tetrameric variant with reduced immunogenicity |
| **Category** | Bispecific Antibody |

---

## V9 Scoring (Validated 2026-02-06)

| Metric | Score |
|--------|-------|
| **Patentability** | 6.75/10.0 |
| **In Silico Enablement** | 9.0/10.0 |
| **Commercial Value** | 7.5/10.0 |
| **Composite (P+S+C)** | 23.25/30.0 |
| **rNPV Estimate** | $95.0M |

---

## Sequence Status

**Status: IN DEVELOPMENT**

Antibody sequences are currently being optimized through computational design. Final VH/VL sequences with validated framework features will be provided upon completion of the design cycle.

---

## Computational Data Status

Computational validation data for this bispecific program is being consolidated and will include:

| Analysis Type | Tools | Planned Outputs |
|---------------|-------|----------------|
| Structural Modeling | Boltz-2 | CIF structures, confidence scores |
| Aggregation Analysis | Aggrescan3D | APR mapping reports |
| Variant Design | ProteinMPNN + RFdiffusion | Optimized sequences |
| Validation | EvoEF2, NetSolP, ThermoMPNN, DeepImmuno | Stability, solubility, immunogenicity predictions |

**Data availability:** Upon request for due diligence purposes.

---

## Original Analysis

**Summary:** Optimized tetrameric PD-1 x CTLA-4 bispecific antibody variants with reduced immunogenicity and improved manufacturability for global market entry.

**Patentability Score:** 6.75/10
**In-Silico Score:** 9.0/10
**Gemini rNPV:** $95.0M

**Patentability Analysis:**
Cadonilimab (AK104) is prior art (approved 2022 in China for cervical cancer). Novelty relies on specific mutations reducing immunogenicity and aggregation. Patentability as a selection invention requires demonstration of unexpected technical effects (e.g., reduced immunogenicity, better stability) against the parent molecule through comparative experimental data.

**In-Silico Analysis:**
Computational validation using Boltz-2 for structure prediction, ProteinMPNN/RFdiffusion for variant design, and Aggrescan3D/DeepImmuno for developability assessment. Analysis predicts improvements in solubility, stability, and immunogenicity. Experimental validation required to confirm predictions.